In a phase 3 clinical trial, treatment with the anti-PD-1 antibody nivolumab significantly improved overall survival compared to everolimus, a standard therapy for advanced ccRCC [61]. Here, PDCD1 is linked to nonpapillary renal cell carcinoma.